A clinical pilot study to evaluate collagen cross-linking (CXL) as a treatment for bacterial keratitis

To study the effect of collagen cross-linking (CXL) as a primary treatment for bacterial keratitis in two ophthalmological centres, through a non-randomised clinical pilot study of twenty patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN21432643

Enrollment

Registered

2010-01-22

Start date

2009-03-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial keratitis Eye Diseases Keratitis

Interventions

Please note that as of 03/08/10 the status of this trial was changed to completed. The previously anticipated end date was 31/12/10. The decision was made to end the trial after the inclusion of 16 pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To be included in the study all patients must fulfil the following criteria: 1. Suspected bacterial keratitis 2. Aged 18 years or above, either sex 3. Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Any antibiotic treatment for the current episode of keratitis 2. Suspicion of a non-bacterial keratitis 3. Pachymetry values under 400 mm 4. Pregnancy or breast-feeding 5. Allergy towards riboflavin or any substance in Ricrolin® 6. Participation in any ophthalmological study in which the follow-up is not completed 7. The patient might not be able to complete the follow-up after treatment required in the study

Design outcomes

Primary

Measure	Time frame
Healing of the epithelium and arrest of corneal melting at two consecutive visits.	—

Secondary

Measure	Time frame
Any side effects and complications of treatment.	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026